Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF pharmacokinetics in breastfeeding women with hepatitis B
ACTRN12619000419167Phase 4Completed
- Sponsor
- South Western Sydney Local Health District
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in hepatitis B (HBV), sponsored by South Western Sydney Local Health District. Primary endpoint: Composite primary pharmacokinetic outcome. Started Mar 2019; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ACTRN12619000419167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000419167.